RSPI RespireRx Pharmaceuticals
Cannabinoids is a broad term to describe the pharmacologically active naturally occurring substances found within the cannabis (marijuana) plant. While the liberalization of state laws regulating the use and sales of marijuana has created a major industry based on the commercialization of marijuana for both medical and recreational use, the U.S. Food and Drug Administration (“FDA”) has not recognized or approved the marijuana plant as medicine nor is it federally legal to sell products that contain cannabinoids as drugs, dietary supplements or foods (edibles) without its approval. From a scientific and pharmaceutical perspective, however, we do not think that pharmaceutical cannabinoids should suffer from the stigma that marijuana has, since it was declared a controlled substance in the 1930’s. We believe that cannabinoids should be considered pharmaceuticals developed under FDA and comparable international regulatory bodies that happen to have been originally derived from plants much like aspirin, theophylline or tamoxifen.
Company profile
Ticker
RSPI, RSPID
Exchange
Website
CEO
Arnold S. Lippa
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
CORTEX PHARMACEUTICALS INC/DE/
SEC CIK
Corporate docs
IRS number
330303583
RSPI stock data
()
Investment data
Securities sold
Number of investors
Calendar
31 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 216 | 216 | 216 | 216 | 216 | 216 |
Cash burn (monthly) | 425.33 | (positive/no burn) | 437.33K | 239.99K | 81.43K | 33.18K |
Cash used (since last report) | 2.76K | n/a | 2.84M | 1.56M | 528.15K | 215.2K |
Cash remaining | -2.54K | n/a | -2.84M | -1.56M | -527.94K | -214.99K |
Runway (months of cash) | -6.0 | n/a | -6.5 | -6.5 | -6.5 | -6.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep 20 | Jeff Eliot Margolis | Common Stock | Conversion | Aquire C | Yes | No | 0 | 5,017,144 | 0 | 5,142,351 |
30 Sep 20 | Jeff Eliot Margolis | Common Stock | Conversion | Aquire C | Yes | No | 0 | 5,017,144 | 0 | 5,142,351 |
30 Sep 20 | Jeff Eliot Margolis | Common Stock | Conversion | Aquire C | Yes | No | 0 | 91,871,094 | 0 | 96,151,863 |
30 Sep 20 | Jeff Eliot Margolis | Warrants (to purchase Common Stock) Common Stock | Conversion | Aquire C | Yes | No | 0.007 | 5,017,144 | 35.12K | 5,017,144 |
30 Sep 20 | Jeff Eliot Margolis | Warrants (to purchase Common Stock) Common Stock | Conversion | Aquire C | Yes | No | 0.007 | 5,017,144 | 35.12K | 5,017,144 |
30 Sep 20 | Jeff Eliot Margolis | Warrants (to purchase Common Stock) Common Stock | Conversion | Aquire C | Yes | No | 0.007 | 91,871,094 | 643.1K | 91,871,094 |
30 Sep 20 | Jeff Eliot Margolis | Series H Preferred Stock Conversion Units | Gift | Aquire G | Yes | No | 0.0064 | 7 | 0.04 | 32.11 |
30 Sep 20 | Jeff Eliot Margolis | Series H Preferred Stock Conversion Units | Gift | Dispose G | No | No | 0.0064 | 7 | 0.04 | 0 |
30 Sep 20 | Jeff Eliot Margolis | Series H Preferred Stock Conversion Units | Gift | Aquire G | Yes | No | 0.0064 | 7 | 0.04 | 32.11 |
30 Sep 20 | Jeff Eliot Margolis | Series H Preferred Stock Conversion Units | Gift | Dispose G | No | No | 0.0064 | 7 | 0.04 | 7 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Management Discussion
- The Company’s unaudited consolidated statements of operations as discussed herein are presented below.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absorb, ADME, Alexa, amnesia, ascending, Attorney, auxiliary, began, behalf, bench, beneficiary, biotechnology, bona, book, broaden, broadly, brought, buy, calendar, candidate, caution, cautionary, certainty, chain, choose, civil, CMC, coined, commensurate, compete, confidence, consumer, consuming, contemplated, correct, correspondingly, cure, customer, Dawn, deadline, deal, decline, delisted, deposit, deposited, designee, desist, Dickason, difficulty, diminished, director, discourage, dispose, disposing, disproportionately, divert, dividend, downgrade, downturn, duty, economy, Emily, encounter, endocannabinoid, environment, exacerbated, excretion, exert, exerting, expend, expended, expenditure, fail, fall, fide, fiduciary, figure, FINRA, Fire, fluctuate, foreseeable, fruition, furnish, GABAAsubtype, governance, governing, government, great, growing, grown, GW, hard, healthcare, heightening, hurt, illustrated, impede, implied, impose, imposed, improper, inability, inaccurate, inefficiency, influence, infrastructure, instrument, intangible, intensify, interfering, invoicing, issuer, knowledge, line, litigation, local, located, lose, loyalty, Manhattan, Matthew, mind, misconduct, modify, momentum, monetary, Nabiximol, neuropathy, newly, nominating, oromucosal, OTC, oversight, oxygen, pattern, PD, penny, Pharma, pharmacodynamic, pilot, Pink, PK, plc, precipitously, Preclincial, prevailing, professional, profitability, prohibit, prosecution, proxy, purity, quotation, rail, rare, recommend, recommended, recommending, recruit, recruiting, reissued, remediate, repurposing, resale, Respire, reverse, risky, screening, seasoned, sentiment, settle, Shane, shortest, speculative, spend, spending, split, sporadically, spouse, spray, spread, steady, strain, successor, suitable, surviving, tandem, tangible, temporary, terminology, THC, thinly, tier, timeframe, titled, tradename, transitional, transparent, trust, trustee, typically, unavailable, undue, uneconomical, unemployment, unenforced, unexpected, unknown, unpredictable, unsafe, upfront, venture, view, viewed, vii, violation, virtually, vitro, voluntarily, webcast, Wisconsin
Removed:
aberrant, abnormal, adherence, adulthood, Advancement, affecting, aged, aggression, agonistic, Alberta, allele, amelioration, anesthetic, announce, antagonist, antagonistic, aripiprazole, ASD, attended, autism, autistic, behavioral, biomarker, blind, branded, categorized, CDC, clarified, climate, Clustered, collapsing, comprising, configuration, connectivity, consumption, core, counsel, CRISPR, CSA, curative, desensitization, Diego, disordered, dispute, disputed, disrupted, dominant, double, dramatic, dysfunction, editing, Edmonton, educational, elusive, emotional, environmental, etiologic, etiology, evidenced, expanded, expansion, explore, extreme, facilitation, Fragile, FXS, gene, generation, genome, glutamatergic, granting, guard, healthy, identifiable, inclusion, infection, instability, interpersonal, Interspaced, introduced, invoked, irritability, jaw, language, largest, light, LTF, MAD, malfunction, Mandibular, mask, mechanical, medicinal, modulate, molecular, mood, mutation, naloxone, naturally, negotiate, neurodevelopmental, opening, output, Palindromic, persist, person, phenotype, physical, physiological, play, political, population, positively, prescription, prevalence, prevention, pullback, purported, ranging, reallocate, rebuilding, remained, representation, retained, Retaining, risen, risperidone, San, sense, sequence, sequencing, showed, signal, slightly, smell, spectrum, splint, Stargazin, stimulating, stimuli, studied, studying, subtle, surgically, synapse, syndrome, TEC, teenage, tentatively, thought, Today, trafficking, transmembrane, transmitter, TRD, UCSD, understand, uvulopalatopharyngoplasty, valuable, verbal, voice
Financial reports
NT 10-K
Notice of late annual filing
31 Mar 21
10-Q
2020 Q3
Quarterly report
23 Nov 20
NT 10-Q
Notice of late quarterly filing
16 Nov 20
10-Q
2020 Q2
Quarterly report
19 Aug 20
NT 10-Q
Notice of late quarterly filing
14 Aug 20
10-Q
2020 Q1
Quarterly report
20 May 20
NT 10-Q
Notice of late quarterly filing
14 May 20
10-K
2019 FY
Annual report
14 Apr 20
NT 10-K
Notice of late annual filing
30 Mar 20
10-Q
2019 Q3
Quarterly report
19 Nov 19
Current reports
8-K
Securities Purchase Agreement
5 Apr 21
8-K
Securities Purchase Agreement
19 Feb 21
8-K
Entry into a Material Definitive Agreement
20 Jan 21
8-K
RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
5 Jan 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Dec 20
8-K
Entry into a Material Definitive Agreement
1 Dec 20
8-K
Amendments to Articles of Incorporation or Bylaws
25 Nov 20
8-K
Regulation FD Disclosure
12 Nov 20
8-K
Entry into a Material Definitive Agreement
5 Oct 20
8-K
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development
25 Sep 20
Registration and prospectus
424B3
Prospectus supplement
19 Feb 21
424B3
Prospectus supplement
8 Feb 21
424B3
Prospectus supplement
1 Dec 20
424B3
Prospectus supplement
24 Nov 20
424B3
Prospectus supplement
28 Oct 20
S-1/A
IPO registration (amended)
26 Oct 20
S-1
IPO registration
14 Oct 20
S-8
Registration of securities for employees
15 Sep 20
D
$193.25K in debt / options / securities to be acquired, sold $193.25K, 2 investors
12 Aug 20
D
$2M in equity / debt, 1 investor
12 Aug 20
Proxies
DEF 14A
Definitive proxy
30 Oct 20
PRER14A
Preliminary revised proxy
30 Oct 20
PRE 14A
Preliminary proxy
20 Oct 20
DEF 14C
Information statement
10 Apr 20
PRE 14C
Preliminary information
24 Mar 20
DEF 14A
Definitive proxy
7 Jul 16
PRE 14A
Preliminary proxy
6 Jun 16
DEF 14C
Information statement
12 May 15
PRE 14C
Preliminary information
22 Apr 15
DEF 14C
Information statement
11 Jun 14
Other
UPLOAD
Letter from SEC
1 Nov 20
EFFECT
Notice of effectiveness
29 Oct 20
CORRESP
Correspondence with SEC
27 Oct 20
UPLOAD
Letter from SEC
27 Oct 20
CORRESP
Correspondence with SEC
25 Oct 20
UPLOAD
Letter from SEC
15 Oct 20
CT ORDER
Confidential treatment order
20 Dec 18
UPLOAD
Letter from SEC
12 May 15
CORRESP
Correspondence with SEC
10 May 15
UPLOAD
Letter from SEC
30 Apr 15
Ownership
SC 13G
RespireRx Pharmaceuticals / SAFRANEK JOHN ownership change
22 Mar 21
4
RespireRx Pharmaceuticals / David Dickason ownership change
6 Oct 20
3
RespireRx Pharmaceuticals / David Dickason ownership change
6 Oct 20
4
RespireRx Pharmaceuticals / Timothy L. Jones ownership change
2 Oct 20
4
RespireRx Pharmaceuticals / Katie MacFarlane ownership change
2 Oct 20
4
RespireRx Pharmaceuticals / Arnold Lippa ownership change
2 Oct 20
4
RespireRx Pharmaceuticals / Jeff Eliot Margolis ownership change
2 Oct 20
4
RespireRx Pharmaceuticals / Katie MacFarlane ownership change
4 Aug 20
4
RespireRx Pharmaceuticals / Richard David Jr. Purcell ownership change
4 Aug 20
4
RespireRx Pharmaceuticals / Timothy L. Jones ownership change
4 Aug 20
Reddit threads
Is anyone else having a second week of red and everything plummeting or just me
22 Feb 21
DFV is handsome and composed.
20 Feb 21
Posting on behalf of a friend. Long live the STONKS! 💎🤚
20 Feb 21
Not the hero we deserved, But the hero we needed. 🙏🏻
20 Feb 21
Welcome... to GME park
20 Feb 21
In the wake of the congressional hearings, financial reporters reach out to some r/wsb users to better understand the community:
19 Feb 21